Who
Shu-Chih Chen
Director
Company insider
Files Form 4 as: Chief Scientific Officer, Atossa Therapeutics.
In numbers
- Trades disclosed
- 23
- Buys
- 3
- Sells
- 1
- Bought
- $24K
- Sold
- $41K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 11 Mar 2013
- Last trade
- 12 May 2026
- Last filed
- 14 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 May 2026filed 14 May 2026 | ATOS Atossa TherapeuticsBiotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 12 May 2026filed 14 May 2026 | ATOS Atossa TherapeuticsBiotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 15 May 2025filed 16 May 2025 | ATOS Atossa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 27 Jun 2024filed 1 Jul 2024 | ATOS Atossa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 4 May 2023filed 5 May 2023 | ATOS Atossa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 13 May 2022filed 16 May 2022 | ATOS Atossa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 14 May 2021filed 18 May 2021 | ATOS Atossa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 15 May 2020filed 19 May 2020 | ATOS Atossa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 17 May 2019filed 21 May 2019 | ATOS Atossa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 27 Jun 2018filed 29 Jun 2018 | ATOS Atossa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 30 May 2018filed 31 May 2018 | ATOS Atossa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | $8,0008 at $1,000.00 | filing |
| 30 May 2018filed 31 May 2018 | ATOS Atossa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | $2.3M2,272 at $1,000.00 | filing |
| 24 May 2017filed 26 May 2017 | ATOS Atossa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,202 at $0.00 | filing |
| 18 May 2016filed 19 May 2016 | ATOS Atossa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —151,516 at $0.00 | filing |
| 9 Mar 2016filed 10 Mar 2016 | ATOS Atossa TherapeuticsBiotechnology | SEC FORM 4 Bought | $5,55015,000 at $0.37 | filing |
| 16 Feb 2016filed 17 Feb 2016 | ATOS Atossa TherapeuticsBiotechnology | SEC FORM 4 Bought | $7,95015,000 at $0.53 | filing |
| 19 Jan 2016filed 21 Jan 2016 | ATOS Atossa TherapeuticsBiotechnology | SEC FORM 4 Bought | $10K50,000 at $0.20 | filing |
| 6 May 2014filed 8 May 2014 | ATOS Atossa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 1 Oct 2013filed 3 Oct 2013 | ATOS Atossa TherapeuticsBiotechnology | SEC FORM 4 Sold | $41K7,265 at $5.66 | filing |
| 18 Jul 2013filed 14 Feb 2014 | ATOS Atossa TherapeuticsBiotechnology | SEC FORM 4 Code G | —100,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.